Anatomy

TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024
Anatomy, Event, Webcast

MALVERN, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will report fourth quarter and full year 2023 financial results on Thursday, March 21, 2024.

Key Points: 
  • MALVERN, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will report fourth quarter and full year 2023 financial results on Thursday, March 21, 2024.
  • TELA Bio’s management will host a conference call and webcast at 4:30 p.m.
  • ET that day to discuss the financial results and provide a corporate update.
  • Participants are required to register a day in advance or at minimum 15 minutes before the start of the call.

SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance

Retrieved on: 
Monday, February 26, 2024
International, Investment, Physician, Record, Worldwide, CPT, Deformity, DSM-IV codes, Webcast, Patient, Anatomy, Research, Travel, Depreciation, Pharmaceutical industry

Gross margin was ~74% for the fourth quarter 2023, compared to ~84% in the corresponding period in 2022.

Key Points: 
  • Gross margin was ~74% for the fourth quarter 2023, compared to ~84% in the corresponding period in 2022.
  • The fourth quarter 2023 gross margin also reflects a ~4 percentage point reduction from a $1.7 million excess inventory reserve.
  • Operating expenses increased ~8% to $41.2 million in the fourth quarter 2023, compared to $38.2 million in the corresponding period in 2022.
  • SI-BONE will host a conference call to discuss the fourth quarter 2023 financial results after market close on Monday, February 26, 2024 at 4:30 P.M. Eastern Time.

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, February 23, 2024
Compensated emancipation, Employment, Anatomy

MALVERN, Pa., Feb. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,800 shares of its common stock to five newly-hired employees, with a grant date of February 21, 2024 (the "Grant Date").

Key Points: 
  • MALVERN, Pa., Feb. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,800 shares of its common stock to five newly-hired employees, with a grant date of February 21, 2024 (the "Grant Date").
  • The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
  • The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.

RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy

Retrieved on: 
Thursday, February 22, 2024
Retinitis pigmentosa, Liver, OTCQB, Cancer, Cataract, Alzheimer's disease, MD, Inflammation, Retina, Systemic disease, Patent, Swelling, Huntington's disease, Eye, Geography, Optical flow, Disease, Connective tissue, Biomarker, Anatomy, Kidney disease, Emaciation, Heart, Diagnosis, Conformation, Risk, Atrophy, Element, Cystic fibrosis, Parkinson's disease, Brain, Medical imaging

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.

Key Points: 
  • PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.
  • The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes.
  • Furthermore, it allows for the detection and analysis of various conditions of the eye, such as, hydration, innervations, inflammation, circulation, nerve conduction, etc.
  • Some of the best-studied ocular conformational diseases include cataracts in the lens and retinitis pigmentosa in the retina.

Route 92 Medical Announces Completion of Enrollment in the SUMMIT MAX Clinical Trial

Retrieved on: 
Wednesday, February 21, 2024
SAN, Medicine, Ambient occlusion, Randomized controlled trial, Catheter, MD, Principal, FDA, Route, Reperfusion, Safety, Radiology, Patient, Anatomy, Neurosurgery, RCT, DRS, MAX, Brain, Pharmaceutical industry

SAN MATEO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the completion of enrollment in its 250-patient SUMMIT MAX clinical trial ( NCT05018650 ) evaluating the safety and effectiveness of its HiPoint™ 88 and HiPoint 70 Reperfusion Catheters as part of the MonopointⓇ Reperfusion System.

Key Points: 
  • SAN MATEO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the completion of enrollment in its 250-patient SUMMIT MAX clinical trial ( NCT05018650 ) evaluating the safety and effectiveness of its HiPoint™ 88 and HiPoint 70 Reperfusion Catheters as part of the MonopointⓇ Reperfusion System.
  • SUMMIT MAX is the first FDA-approved aspiration thrombectomy trial which is randomized.
  • Randomized controlled trials provide the best clinical science and the SUMMIT MAX Trial compares the Route 92 Medical Monopoint System to the largest commercially available conventional aspiration system.
  • “Route 92 Medical is leading the way in neurovascular innovation technology, bringing clinicians complete solutions designed to improve endovascular thrombectomy procedure times and outcomes.

J. Kurt Jacobus, Ph.D. Joins CurvaFix Board of Directors

Retrieved on: 
Tuesday, March 5, 2024
Medical Devices, Health, Surgery, Other Health, General Health, Biotechnology, Acquisition, Champaign–Urbana metropolitan area, Bone fracture, Enovis, Mechanical, Foot, Doctor of Philosophy, Pelvis, NuVasive, University, Mechanical engineering, Patient, Anatomy, Science, Trauma, Research, Nursing

CurvaFix, Inc ., a developer of medical devices that deliver stable fixation for curved anatomy and poor bone quality, announced today the appointment of J. Kurt Jacobus, Ph.D., as the newest member of its Board of Directors.

Key Points: 
  • CurvaFix, Inc ., a developer of medical devices that deliver stable fixation for curved anatomy and poor bone quality, announced today the appointment of J. Kurt Jacobus, Ph.D., as the newest member of its Board of Directors.
  • “We are delighted to welcome Kurt to CurvaFix’s Board of Directors,” said Mark Foster, CEO at CurvaFix.
  • “His extensive experience and proven track record of success in the orthopedic medical device sector makes him an invaluable addition to our board.
  • “I am honored to join CurvaFix’s excellent Board of Directors,” said Dr. Jacobus.

Foldax, Inc. Signs Manufacturing Agreement with Dolphin Life Science India LLP to Expedite Upcoming Commercial Availability

Retrieved on: 
Tuesday, February 27, 2024
Research, Medical Devices, Engineering, Chemicals, Plastics, Health Technology, Cardiology, Manufacturing, Biotechnology, Health, Science, Anticoagulant, Cardiovascular disease, CDSCO, Sale, RHD, Calcification, Mitral valve, Patient, Anatomy, LLP, Failure, DCGI, TRIA, Medical device

Foldax® Inc., a pioneer in the development of innovative, polymer heart valves, today announced a manufacturing agreement with Dolphin Life Science India LLP to enable in-country manufacturing of the TRIA™ polymer mitral surgical heart valve outside of the U.S. for the first time.

Key Points: 
  • Foldax® Inc., a pioneer in the development of innovative, polymer heart valves, today announced a manufacturing agreement with Dolphin Life Science India LLP to enable in-country manufacturing of the TRIA™ polymer mitral surgical heart valve outside of the U.S. for the first time.
  • The TRIA mitral valve is designed specifically to accommodate the anatomy and pressures of the mitral position.
  • Dolphin Life Science India LLP is an expert in manufacturing medical devices.
  • The company is registered with India’s regulatory bodies, the Drugs Controller General of India (DCGI), and the Central Drugs Standard Control Organization (CDSCO).

First shoulder arthroplasty surgeries using Stryker’s Blueprint® Mixed Reality Guidance System completed in Europe

Retrieved on: 
Wednesday, February 28, 2024
Software, Hardware, Surgery, General Health, Health, Medical Devices, Health Technology, Technology, Hospital, Doctor of Philosophy, Multimedia, MD, Shoulder joint, Surgeon, Blueprint, HoloLens 2, SYK, Safety, Patient, Anatomy, Orientation, Microsoft, Dentistry

View the full release here: https://www.businesswire.com/news/home/20240227354011/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240227354011/en/
    Stryker's Blueprint Mixed Reality Guidance System offers shoulder arthroplasty surgeons a new tool to execute their pre-operative plan.
  • (Photo: Business Wire)
    “It’s exciting to be one of the first two hospitals in Europe to use Stryker’s Mixed Reality Guidance System,” said Professor Berhouet.
  • Blueprint Mixed Reality Guidance System allows surgeons and their instruments to be ‘guided’ by 3D images and guidance widgets, which can be displayed on the patient and in the surgeon’s line of sight without disrupting normal workflow.
  • The MR Guidance system received a CE mark at the end of 2023 and the first surgeries globally were performed in the U.S. and Canada in December 2023.

Countertrade & Offset Service: Track Changes in Government Regulations and Compare your Company's Strategy with your Competitor's - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 20, 2024
Professional Services, Business, Defense, Other Professional Services, Other Defense, Contracts, Intelligence, Commerce, Government, Policy, Anatomy, Publication

There are only two publications that exclusively provide a constant flow of intelligence on these subjects.

Key Points: 
  • There are only two publications that exclusively provide a constant flow of intelligence on these subjects.
  • "Countertrade & Offset", now in its 24th year, is published twice every month.
  • Indispensable for any major defence, trading, or financial company, and for government officials in the Ministries of Defence, Economy, Trade, or Commerce.
  • "The Offset Guidelines Quarterly Bulletin", comprehensive details of each countries guidelines including the policies of those countries that don't publish details.

OrthoVentions Invests in Motio[OV] to Develop 3D Printed Implant and Instruments to Treat Joint Arthritis of the Big Toe

Retrieved on: 
Friday, March 8, 2024
Ankle, Ageing, Pain, 3D, Hospital, Foot, MTP, HSS, Arthritis, Anatomy, Partnership, Dentistry

MotioOV is developing a novel 3D printed implant and custom instruments to address stiffness and pain associated with arthritis of the first metatarsophalangeal (MTP) joint.

Key Points: 
  • MotioOV is developing a novel 3D printed implant and custom instruments to address stiffness and pain associated with arthritis of the first metatarsophalangeal (MTP) joint.
  • The solution under development will consist of various implant sizes and single-use instruments customized to complete total joint arthroplasty.
  • Complaints of arthritic toe pain account for 20-30 percent of all patient visits to foot and ankle surgeon's practice.
  • Arthritis of the MTP joint is a growing clinical burden driven by the aging population with no viable motion preserving option."